Akeso advances cancer immunotherapy as Ivonescimab reaches Phase III milestone in lung cancer treatment
Akeso, Inc. (9926.HK) has completed patient enrollment for its pivotal Phase III trial (HARMONi-6), marking a significant step in its mission to redefine first-line treatment ... Read More
Akeso Biopharma raises $250m to accelerate international clinical trials
Akeso Biopharma has successfully raised approximately $250 million through a share placement, drawing significant recognition from international investment firms. The placement saw a majority of ... Read More
Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the HARMONi Phase III clinical trial. This pivotal ... Read More